

ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON AND PARIS

GHENT, Belgium, 9 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announces that it will participate in the following upcoming investor conferences taking place in London, UK and Paris, France:

Jefferies 2017 Healthcare Conference in London: a presentation is scheduled for Thursday 16 November 2017 at 02:00 p.m. GMT (03:00 p.m. Central European Time) together with one-on-one meetings with institutional investors. The presentation, given by Dr Edwin Moses, CEO of Ablynx, will be webcast live and can be accessed on the day via this link. The presentation will be available on the Company's website, under the News & Events section for 90 days following the event. Bryan, Garnier & Co Annual Healthcare Conference in Paris: one-on-one meetings with institutional investors are scheduled for Friday 17 November 2017. [About Ablynx](#)

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact Ablynx: Dr Edwin Moses CEO t: +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e: edwin.moses@ablynx.com

Lies Vanneste Director Investor Relations t: +32 (0)9 262 01 37 m: +32 (0)498 05 35 79 e: lies.vanneste@ablynx.com

lies.vanneste@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations: Consilium Strategic Communications Mary-Jane Elliott, Philippa Gardner, Sukaina Virjit: +44 (0)20 3709 5700 e: ablynx@consilium-comms.com

Disclaimer Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

pdf version of the press release This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Ablynx via Globenewswire

<https://www.bioportfolio.com/news/article/3411422/Ablynx-To-Present-At-Upcoming-Investor-Conferences-In-London-And-Paris.html>